Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-7479d7b7d-t6hkb Total loading time: 0 Render date: 2024-07-09T12:22:24.476Z Has data issue: false hasContentIssue false

Chapter 2 - Anticholinergic agents in the management of Parkinson's disease

from Section I - The Pharmacological Basis for Parkinson's Disease Treatment

Published online by Cambridge University Press:  05 March 2016

By
Juan Carlos Giugni  and
Ramon L. Rodriguez-Cruz
Edited by
Néstor Gálvez-Jiménez ,
Hubert H. Fernandez ,
Alberto J. Espay  and
Susan H. Fox
Néstor Gálvez-Jiménez
Affiliation:
Cleveland Clinic, Florida
Hubert H. Fernandez
Affiliation:
Cleveland Clinic, Ohio
Alberto J. Espay
Affiliation:
University of Cincinnati
Susan H. Fox
Affiliation:
Toronto Western Hospital
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Parkinson's Disease
Current and Future Therapeutics and Clinical Trials
 , pp. 5 - 12
Publisher: Cambridge University Press
Print publication year: 2016

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Standaert, DG, Roberson, ED. Treatment of central nervous system degenerative disorders. In: Hardman, JG, Molinoff, PB, Ruddon, RW and Gilman, AG, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. New York: McGraw-Hill, 1995; 503–19.Google Scholar
Schwab, RS, Tillmann, WR. Artane in the treatment of Parkinson's disease; a report of its effectiveness alone and in combination with benadryl and parpanit. N Engl J Med, 1949; 241: 483–5.CrossRefGoogle ScholarPubMed
Ordenstein, L, Sur la Paralysie Agitante et la Sclérose en Plaques Generalisée., 1867; Paris: Martinet (two leaves of color plates).Google Scholar
Goetz, CG. The history of Parkinson's disease: early clinical descriptions and neurological therapies. Cold Spring Harb Perspect Med 2011; 1: a008862.Google Scholar
Aosaki, T. Miura, M, Suzuki, T, Nishimura, K, Masuda, M. Acetylcholine-dopamine balance hypothesis in the striatum: an update. Geriatr Gerontol Int 2010; 10 (Suppl. 1): S148–57.Google Scholar
Duvoisin, RC. Cholinergic-anticholinergic antagonism in parkinsonism. Arch Neurol 1967; 17: 124–36.CrossRefGoogle ScholarPubMed
Zhou, FM, Liang, Y, Dani, JA. Endogenous nicotinic cholinergic activity regulates dopamine release in the striatum. Nat Neurosci 2001; 4: 1224–9.CrossRefGoogle ScholarPubMed
Graybiel, AM. Neurochemically specified subsystems in the basal ganglia. Ciba Found Symp 1984; 107: 114–49.Google Scholar
DeLong, M, Wichmann, T. Update on models of basal ganglia function and dysfunction. Parkinsonism Relat Disord 2009; 15 (Suppl. 3): S237–40.CrossRefGoogle ScholarPubMed
Bolam, JP. Synapses of identified neurons in the neostriatum. Ciba Found Symp 1984; 107: 30–47.Google Scholar
Kawaguchi, Y, Wilson, CJ, Augood, SJ, Emson, PC. Striatal interneurones: chemical, physiological and morphological characterization. Trends Neurosci 1995; 18: 527–35.CrossRefGoogle ScholarPubMed
Pakhotin, P, Bracci, E. Cholinergic interneurons control the excitatory input to the striatum. J Neurosci 2007; 27: 391–400.Google Scholar
Benarroch, EE. Effects of acetylcholine in the striatum. Recent insights and therapeutic implications. Neurology 2012; 79: 274–81.CrossRefGoogle ScholarPubMed
Rinne, JO, Ma, SY, Lee, MS, Collan, Y, Röyttä, M. Loss of cholinergic neurons in the pedunculopontine nucleus in Parkinson's disease is related to disability of the patients. Parkinsonism Relat Disord 2008; 14: 553–7.Google Scholar
Jellinger, K. The pedunculopontine nucleus in Parkinson's disease, progressive supranuclear palsy and Alzheimer's disease. J Neurol Neurosurg Psychiatry 1988; 51: 540–3.Google Scholar
Benarroch, EE. Pedunculopontine nucleus: functional organization and clinical implications. Neurology 2013; 80: 1148–55.CrossRefGoogle ScholarPubMed
Wang, HL, Morales, M. Pedunculopontine and laterodorsal tegmental nuclei contain distinct populations of cholinergic, glutamatergic and GABAergic neurons in the rat. Eur J Neurosci 2009; 29: 340–58.CrossRefGoogle ScholarPubMed
Griffiths, PD, Sambrook, MA, Perry, R, Crossman, AR. Changes in benzodiazepine and acetylcholine receptors in the globus pallidus in Parkinson's disease. J Neurol Sci 1990; 100: 131–6.Google Scholar
Sweeney, PJ. Parkinson's disease: managing symptoms and preserving function. Geriatrics 1995; 50: 24–31.Google Scholar
Quik, M, O'Leary, K, Tanner, CM. Nicotine and Parkinson's disease: implications for therapy. Mov Disord 2008; 23: 1641–52.CrossRefGoogle ScholarPubMed
Ebersbach, G, Stöck, M, Müller, J, et al. Worsening of motor performance in patients with Parkinson's disease following transdermal nicotine administration. Mov Disord 1999; 14: 1011–13.Google Scholar
Lemay, S, Chouinard, S, Blanchet, P, et al. Lack of efficacy of a nicotine transdermal treatment on motor and cognitive deficits in Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 31–9.Google Scholar
Krueger, BK. Kinetics and block of dopamine uptake in synaptosomes from rat caudate nucleus. J Neurochem 1990; 55: 260–7.Google Scholar
McDonough, JH Jr, Shih, TM. A study of the N-methyl-d-aspartate antagonistic properties of anticholinergic drugs. Pharmacol Biochem Behav 1995; 51: 249–53.CrossRefGoogle ScholarPubMed
Whiteman, PD, Fowle, AS, Hamilton, MJ, et al. Pharmacokinetics and pharmacodynamics of procyclidine in man. Eur J Clin Pharmacol 1985; 28: 73–8.Google Scholar
Grimaldi, R, Perucca, E, Ruberto, G, et al. Pharmacokinetic and pharmacodynamic studies following the intravenous and oral administration of the antiparkinsonian drug biperiden to normal subjects. Eur J Clin Pharmacol 1986; 29: 735–7.Google Scholar
Yokogawa, K, Nakashima, E, Ishizaki, J, et al. Brain regional pharmacokinetics of biperiden in rats. Biopharm Drug Dispos 1992; 13: 131–40.Google Scholar
Ishizaki, J, Yokogawa, K, Nakashima, E, Ohkuma, S, Ichimura, F. Influence of ammonium chloride on the tissue distribution of anticholinergic drugs in rats. J Pharm Pharmacol 1998; 50: 761–6.CrossRefGoogle ScholarPubMed
Nakashima, E, Yokogawa, K, Ichimura, F, et al. Effects of fasting on biperiden pharmacokinetics in the rat. J Pharm Sci 1987; 76: 10–13.Google Scholar
Paeme, G, Van Bossuyt, H, Vercruysse, A. Phenobarbital induction of procyclidine metabolism: in vitro study. Eur J Drug Metab Pharmacokinet 1982; 7: 229–31.Google Scholar
He, H, McKay, G, Midha, KK. Phase I and II metabolites of benztropine in rat urine and bile. Xenobiotica 1995; 25: 857–72.Google Scholar
Chew, ML, Mulsant, BH, Pollock, BG, et al. Anticholinergic activity of 107 medications commonly used by older adults. J Am Geriatr Soc 2008; 56: 1333–41.CrossRefGoogle ScholarPubMed
Lang, AE. Treatment of Parkinson's disease with agents other than levodopa and dopamine agonists: controversies and new approaches. Can J Neurol Sci 1984; 11 (Suppl.): 210–20.CrossRefGoogle ScholarPubMed
Hughes, AJ, Daniel, SE, Kilford, L, Lees, AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181–4.Google Scholar
Katzenschlager, R, Sampaio, C, Costa, J, Lees, A. Anticholinergics for symptomatic management of Parkinson's disease. Cochrane Database Syst Rev 2003: CD003735.Google Scholar
Thomsen, TR, Galpern, WR, Asante, A, Arenovich, T, Fox, SH. Ipratropium bromide spray as treatment for sialorrhea in Parkinson's disease. Mov Disord 2007; 22: 2268–73.Google Scholar
Arbouw, ME. Movig, KL, Koopmann, M, et al. Glycopyrrolate for sialorrhea in Parkinson disease: a randomized, double-blind, crossover trial. Neurology 2010; 74: 1203–7.Google Scholar
Lloret, SP, Nano, G, Carrosella, A, Gamzu, E, Merello, M. A double-blind, placebo-controlled, randomized, crossover pilot study of the safety and efficacy of multiple doses of intra-oral tropicamide films for the short-term relief of sialorrhea symptoms in Parkinson's disease patients. J Neurol Sci 2011; 310: 248–50.Google Scholar
Bennett, N, O'Leary, M, Patel, AS, et al. Can higher doses of oxybutynin improve efficacy in neurogenic bladder? J Urol 2004; 171: 749–51.CrossRefGoogle ScholarPubMed
Corbin, KB. Trihexyphenidyl; evaluation of the new agent in the treatment of Parkinsonism. J Am Med Assoc 1949; 141: 377–82.Google Scholar
Brumlik, J, Canter, G, Delatorre, R, et al. A critical analysis of the effects of trihexyphenidyl (artane) on the components of the Parkinsonian syndrome. J Nerv Ment Dis 1964; 138: 424–31.Google ScholarPubMed
Iivanainen, M. KR 339 in the treatment of Parkinsonian tremor. Acta Neurol Scand 1974; 50: 469–77.Google Scholar
Poewe, WH, Lees, AJ, Stern, GM. Dystonia in Parkinson's disease: clinical and pharmacological features. Ann Neurol 1988; 23: 73–8.Google Scholar
Jankovic, J. Treatment of dystonia. Lancet Neurol 2006; 5: 864–72.Google Scholar
Machado, D, Jabbari, B. Treatment of Parkinson's disease with anticholinergic medication. In: Pfeiffer, RF., Wszolek, ZK, Ebadi, M, eds. Parkinson's Disease. Boca Raton: CRC Press, 2013; 811–18.Google Scholar
Cantello, R, Riccio, A, Gilli, M, et al. Bornaprine vs placebo in Parkinson disease: double-blind controlled cross-over trial in 30 patients. Ital J Neurol Sci 1986; 7: 139–43.CrossRefGoogle ScholarPubMed
Tourtellotte, WW, Potvin, AR, Syndulko, K, et al. Parkinson's disease: Cogentin with Sinemet, a better response. Prog Neuropsychopharmacol Biol Psychiatry 1982; 6: 51–5.Google Scholar
Baba, Y, Higuchi, MA, Abe, H, et al. Anti-cholinergics for axial symptoms in Parkinson's disease after subthalamic stimulation. Clin Neurol Neurosurg 2012; 114: 1308–11.CrossRefGoogle ScholarPubMed
Koller, WC. Pharmacologic treatment of parkinsonian tremor. Arch Neurol 1986; 43: 126–7.Google Scholar
Parkes, JD, Baxter, RC, Marsden, CD, Rees, JE. Comparative trial of benzhexol, amantadine, and levodopa in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 1974; 37: 422–6.Google Scholar
Schrag, A, Schelosky, L, Scholz, U, Poewe, W. Reduction of Parkinsonian signs in patients with Parkinson's disease by dopaminergic versus anticholinergic single-dose challenges. Mov Disord 1999; 14: 252–5.3.0.CO;2-N>CrossRefGoogle ScholarPubMed
Roberts, J, Waller, DG, von Renwick, AG, et al. The effects of co-administration of benzhexol on the peripheral pharmacokinetics of oral levodopa in young volunteers. Br J Clin Pharmacol 1996; 41: 331–7.Google Scholar
Contin, M, Riva, R, Martinelli, P, et al. Combined levodopa-anticholinergic therapy in the treatment of Parkinson's disease. Effect on levodopa bioavailability. Clin Neuropharmacol 1991; 14: 148–55.CrossRefGoogle ScholarPubMed
Horrocks, M, Vicary, DJ, Rees, JE, Parkes, JD, Marsden, CD. Anticholinergic withdrawal and benzhexol treatment in Parkinson's disease. J Neurol Neurosurg Psychiatry 1973; 36: 936–41.CrossRefGoogle ScholarPubMed
Tune, LE, Anticholinergic effects of medication in elderly patients. J Clin Psychiatry 2001; 62 (Suppl. 21): 11–4.Google Scholar
Buter, TC, van den Hout, A, Matthews, FE, et al. Dementia and survival in Parkinson disease: a 12-year population study. Neurology 2008; 70: 1017–22.Google Scholar
Bohnen, NI, Kaufer, DI, Hendrickson, R, et al. Cortical cholinergic denervation is associated with depressive symptoms in Parkinson's disease and parkinsonian dementia. J Neurol Neurosurg Psychiatry 2007; 78: 641–3.Google Scholar
Ehrt, U, Broich, K, Larsen, JP, Ballard, C, Aarsland, D. Use of drugs with anticholinergic effect and impact on cognition in Parkinson's disease: a cohort study. J Neurol Neurosurg Psychiatry 2010; 81: 160–5.Google Scholar
Bedard, MA, Pillon, B, Dubois, B, et al. Acute and long-term administration of anticholinergics in Parkinson's disease: specific effects on the subcortico-frontal syndrome. Brain Cogn 1999; 40: 289–313.Google Scholar
Cooper, JA, Sagar, HJ, Doherty, SM, et al. Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease. A follow-up study of untreated patients. Brain 1992; 115: 1701–25.Google Scholar
Quik, M, McIntosh, JM. Striatal α6* nicotinic acetylcholine receptors: potential targets for Parkinson's disease therapy. J Pharmacol Exp Ther 2006; 316: 481–9.Google Scholar
Itti, E, Villafane, G, Malek, Z, et al. Dopamine transporter imaging under high-dose transdermal nicotine therapy in Parkinson's disease: an observational study. Nucl Med Commun 2009; 30: 513–18.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×